Management tracks: Gilead, Ipsen, Depomed

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at Novartis AG (NYSE:NVS; SIX:NOVN).

Cancer company Ipsen Group (Euronext:IPN; Pink:IPSEY) promoted Dominique Laymand to EVP, chief ethics and compliance officer from SVP, chief ethics and compliance officer...